Developing Story: The Camizestrant Vote, Doctors Weigh In with Dr. Sarah Sammons & Dr. Neil Vasan

Two weeks ago, we broke down the ODAC vote on camizestrant and SERENA-6 with seven patient advocates. This week, we go deeper — bringing in the clinical and regulatory perspectives from two of the most qualified voices in the field.We're joined by Dr. Sarah Sammons, newly appointed Co-Leader of Breast Oncology at the University of Maryland Greenebaum Comprehensive Cancer Center and former faculty at Dana-Farber Cancer Institute and Harvard Medical School, and Dr. Neil Vasan, Director of Translational Research in Breast Cancer at NYU Langone Health — and the Acting Chair of the FDA's Oncologic Drugs Advisory Committee who sat in that room and cast a vote.Plus, patient advocates Janice Cowden and Abigail Johnston are back to ask the questions the rest of us are thinking.We cover:What SERENA-6 actually proved — and what it didn'tWhy the ODAC voted 6–3 against the ctDNA-guided switching strategyThe four FDA critiques that drove the voteWhat the quality of life data showed — and why regulators couldn't act on itThe persevERA trial and where oral SERDs actually fit right nowWhat the vote means for the future of biomarker-driven trialsThe HERizon-Breast trial and ctDNA-guided scanning on the horizonBreaking news: The FDA has extended the camizestrant review deadline to August 14, 2026, after AstraZeneca submitted a Major Amendment with additional SERENA-6 data. This story isn't over.Show notes and resources at livefromstage4.orgThis episode is for informational purposes only and does not constitute medical advice. Please consult your oncologist about your individual situationThanks for listening. If you enjoyed the episode, subscribe and leave a review — it really helps. Follow us on social media @livefromstage4 and visit our website at www.livefromstage4.org for show notes and links. Your support helps us continue to share important stories and advocate for those living with metastatic breast cancer.Until next time, take care and keep pushing for progress.